3-(4-氯苯基)-2-(9h-芴-9-甲氧基羰基氨基)-丙酸 | 250740-51-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-(4-氯苯基)-2-(9h-芴-9-甲氧基羰基氨基)-丙酸
• 中文别名: FMOC-DL-4-氯苯丙氨酸
• 英文名称: Fmoc-4-chlorophenylalanine
• 英文别名: N-Fmoc-4-Cl-Phe-OH；3-(4-Chloro-phenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-propionic acid；3-(4-chlorophenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
• CAS: 250740-51-3
• 化学式: C₂₄H₂₀ClNO₄
• 分子量: 421.88
• InChiKey: CQPNKLNINBUUOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-氯苯基)-2-(9h-芴-9-甲氧基羰基氨基)-丙酸 、 N-Boc-N-[2-(2-thienyl)ethyl]-2-piperazinebenzylamine 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 生成 tert-butyl N-[[2-[4-[3-(4-chlorophenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoyl]piperazin-1-yl]phenyl]methyl]-N-(2-thiophen-2-ylethyl)carbamate
  参考文献：
  名称：

  Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor

  摘要：

  SAR studies of a series of piperazinebenzylamines resulted in the discovery of potent antagonists of the human melanocortin-4 receptor. Compounds 11c, 11d, and 11l, which had K-i values of 21, 14, and 15 nM, respectively, possessed low efficacy in cAMP stimulation (similar to15% of alpha-MSH maximal level) mediated by MC4R, and functioned as antagonists in inhibition of alpha-MSH-stimulated cAMP release in a dose-dependent manner (11l, IC50 = 36 nM). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.055
• 作为产物：
  描述：

  DL-4-氯苯丙氨酸 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 phosphate buffer 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 3-(4-氯苯基)-2-(9h-芴-9-甲氧基羰基氨基)-丙酸
  参考文献：
  名称：

  Novel Selective Inhibitors of the Interaction of Individual Nuclear Hormone Receptors with a Mutually Shared Steroid Receptor Coactivator 2

  摘要：

  Nuclear hormone receptor (NR) signaling, currently a therapeutic target in multiple diseases, involves an ordered series of protein interactions to regulate transcription in response to changing hormone levels. Later steps in the process of ligand-dependent signaling are driven by a highly conserved interaction between the NRs and the steroid receptor coactivators (SRCs) that is effected by a conserved interaction motif (L1XXL2L3), known as an NR box. Using computational design and combinatorial chemistry, we have produced novel alpha-helical proteomimetics of the second NR box of SRC2 that exploit structural differences between human estrogen receptor alpha (hERalpha), human estrogen receptor beta (hERbeta), and human thyroid hormone receptor beta (hTRbeta). The resulting library sequentially replaced each leucine with non-natural side chains. Screening this library using a quantitative competition assay revealed compounds that selectively inhibit the interaction of SRC2-2 with each individual NR in preference to its interaction with the other NR. This approach generated highly selective compounds from one that had no specificity for a particular family member. These compounds represent the first family-member-selective competitive inhibitors of the protein interactions of transcription factors.

  DOI：

  10.1021/ja0348391

文献信息

• Piperazine- and piperidine-derivatives as melanocortin receptor agonists
  申请人：——

  公开号：US20040082590A1

  公开（公告）日：2004-04-29

  The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction. 1

  本发明涉及公式I的黑素皮质素受体激动剂，可用于治疗肥胖症、糖尿病以及男性和/或女性性功能障碍。
• HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS
  申请人：Lennig Petra

  公开号：US20070197539A1

  公开（公告）日：2007-08-23

  The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments

  该发明涉及用氨基酸取代的六氢吡嗪[1,2-a]嘧啶-4,7-二酮衍生物，以及其生理耐受盐，其制备方法以及作为药物的用途。
• [DE] MIT AMINOSÄUREN SUBSTITUIERTE HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDIN-4, 7-DIONDERIVATE<br/>[EN] HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4, 7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS<br/>[FR] DERIVES D'HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDIN-4,7-DIONE SUBSTITUES PAR DES AMINOACIDES, LEUR PROCEDE DE PRODUCTION, ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
  申请人：SANOFI AVENTIS DEUTSCHLAND

  公开号：WO2006024390A1

  公开（公告）日：2006-03-09

  Die Erfindung betrifft substituierte Hexahydro-pyrazino[1,2-a]pyrimidin-4,7-dionderivate sowie deren physiologisch verträgliche Salze und physiologisch funktionelle Derivate. Es werden Verbindungen der Formel (I), worin die Reste die angegebenen Bedeutungen haben, sowie deren physiologisch verträglichen Salze und Verfahren zu deren Herstellung beschrieben. Die Verbindungen eignen sich z.B. als Anorektika.

  这项发明涉及取代的六氢吡嗪[1,2-a]嘧啶-4,7-二酮衍生物，以及其生理相容性盐和生理功能衍生物。描述了具有以下结构的化合物（I），其中残基具有所示含义，以及其生理相容性盐和制备方法。这些化合物可用作食欲抑制剂。
• Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
  申请人：Flohr Stefanie

  公开号：US20050004131A1

  公开（公告）日：2005-01-06

  Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.

  取代的六氢吡嗪[1,2-a]嘧啶-4,7-二酮衍生物，其制备方法及其用作药物。本发明涉及取代的六氢吡嗪[1,2-a]嘧啶-4,7-二酮衍生物以及其生理耐受盐和生理功能衍生物。描述了具有以下式I的化合物，其中基团具有所述含义，以及其生理耐受盐和制备它们的方法。这些化合物例如适用于作为厌食剂。
• [EN] SOLID-PHASE SYNTHESIS METHOD FOR DEGARELIX<br/>[FR] PROCÉDÉ DE SYNTHÈSE EN PHASE SOLIDE DE DÉGARÉLIX<br/>[ZH] 一种地加瑞克的固相合成方法
  申请人：HYBIO PHARMACEUTICAL CO LTD

  公开号：WO2021103458A1

  公开（公告）日：2021-06-03

  提供了一种地加瑞克的固相合成方法，包括：1)肽树脂的偶联：按照Fmoc固相合成方法，逐个偶联氨基酸Fmoc-D-Ala-OH、Fmoc-Pro-OH、Fmoc-Lys(Boc,iPr)-OH、Fmoc-Leu-OH、Fmoc-D-4Aph(Cbm)-OH、Fmoc-4Aph(Hmb,Hor)-OH、Fmoc-Ser(tBu)-OH、Fmoc-D-3Pal-OH、Fmoc-D-4Cpa-OH以及Fmoc-D-2Nal-OH至固相载体上；2)肽树脂N端乙酰化；3)肽树脂裂解后获得地加瑞克粗肽。